Non-producer multiple myeloma presenting with acute hyperammonemic encephalopathy: case report

Abstract Background Hyperammonemic encephalopathy (HE) is a rare and life-threatening complication of multiple myeloma, with underlying mechanisms that are not fully understood. In contrast to previously reported cases, most of which have been associated with IgG or IgA isotypes, we describe a patie...

Full description

Saved in:
Bibliographic Details
Main Authors: Karina Verma (Author), Tina Zhang (Author), David Mueller (Author), Julie Li (Author), Vaishali Sanchorawala (Author), Andrew Staron (Author)
Format: Book
Published: BMC, 2023-01-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_f2294c4ad9ab4245939296e952807df1
042 |a dc 
100 1 0 |a Karina Verma  |e author 
700 1 0 |a Tina Zhang  |e author 
700 1 0 |a David Mueller  |e author 
700 1 0 |a Julie Li  |e author 
700 1 0 |a Vaishali Sanchorawala  |e author 
700 1 0 |a Andrew Staron  |e author 
245 0 0 |a Non-producer multiple myeloma presenting with acute hyperammonemic encephalopathy: case report 
260 |b BMC,   |c 2023-01-01T00:00:00Z. 
500 |a 10.1186/s13000-022-01285-6 
500 |a 1746-1596 
520 |a Abstract Background Hyperammonemic encephalopathy (HE) is a rare and life-threatening complication of multiple myeloma, with underlying mechanisms that are not fully understood. In contrast to previously reported cases, most of which have been associated with IgG or IgA isotypes, we describe a patient with HE as the presenting symptom of non-producer multiple myeloma (NPMM). Case presentation A 60-year-old man developed lethargy that progressed into coma. He was found to have an elevated ammonia level, despite normal hepatic function. He was diagnosed with HE secondary to NPMM, demonstrating 80% plasma cells without light chain expression in the bone marrow and absence of a monoclonal protein in the serum or urine, including by matrix-assisted laser desorption ionization time-of-flight mass-spectrometry (MASS-FIX). Myeloma-directed therapy with daratumumab, bortezomib, cyclophosphamide and dexamethasone successfully reversed his HE. At clinical relapse, he received salvage chemotherapy followed by venetoclax therapy, leading to a short period of neurological recovery. Conclusions This case demonstrates that HE can occur in a patient with NPMM and challenges the mechanism suggested by limited prior studies; i.e., that excess ammonia in multiple myeloma arises from degradation of M-proteins. We postulate that the neoplastic plasma cells in NPMM have amplified amino acid metabolism, despite lacking detectable intracellular or secreted immunoglobulins. 
546 |a EN 
690 |a Hyperammonemia 
690 |a Multiple myeloma 
690 |a Non-producer 
690 |a MASS-FIX 
690 |a Daratumumab 
690 |a Venetoclax 
690 |a Pathology 
690 |a RB1-214 
655 7 |a article  |2 local 
786 0 |n Diagnostic Pathology, Vol 18, Iss 1, Pp 1-5 (2023) 
787 0 |n https://doi.org/10.1186/s13000-022-01285-6 
787 0 |n https://doaj.org/toc/1746-1596 
856 4 1 |u https://doaj.org/article/f2294c4ad9ab4245939296e952807df1  |z Connect to this object online.